TrialLineage Concept
Medicinal chemistry
Knowing that a protein causes disease is not the same as having a drug that can reach it. Medicinal chemistry is the discipline that bridges that gap — designing, building, and refining small molecules that can interact with a specific biological target inside the human body. This page explains what medicinal chemists do, why their work is a critical and often misunderstood part of drug discovery, and how it connects to the development of KRAS-directed therapies now in clinical trials for pancreatic cancer.
In plain language
What is medicinal chemistry?
Medicinal chemistry is the science of designing molecules that can act as drugs. A medicinal chemist takes what biologists have learned about a disease target — its shape, its behavior, where it sits in the cell — and tries to build a small molecule that can reach that target, bind to it, and change what it does. The molecule has to do all of this while also being safe enough to give to a person, stable enough to survive in the body, and selective enough to affect the target without disrupting too much else.
This is not a single step. It is an iterative process that can take years. Chemists design a molecule, test it, learn what works and what does not, and redesign. Each cycle improves the compound’s potency, selectivity, stability, or safety — or reveals that a particular chemical strategy is a dead end and a new approach is needed. The compound that eventually enters a clinical trial is typically the product of hundreds or thousands of earlier compounds that were made, tested, and set aside.
Core vocabulary
- Hit: an early-stage molecule that shows some activity against the target, usually discovered through screening
- Lead: a more refined compound with enough potency, selectivity, and drug-like properties to be worth optimizing further
- Lead optimization: the iterative process of modifying a lead compound to improve its properties for use in humans
- SAR (structure-activity relationship): the systematic study of how changes to a molecule’s structure affect its biological activity
- Drug candidate: the final optimized compound selected to enter preclinical safety testing and, if successful, clinical trials
Why it matters
Why medicinal chemistry is essential to drug discovery
Biology identifies targets; chemistry makes drugs
Decades of research in oncogene discovery, signaling biology, and disease genomics can identify a protein that drives a disease. But identification is not intervention. Without a molecule that can physically reach the protein, bind to it in a specific way, and alter its function, the biological knowledge remains scientifically important but therapeutically inert. Medicinal chemistry is the discipline that converts a validated target into a testable drug.
It solves problems that biology cannot
A molecule might bind its target perfectly in a test tube but fail in the body because it is broken down by liver enzymes, cannot cross cell membranes, or is cleared too quickly to maintain an effective concentration. These are chemistry problems, not biology problems. Medicinal chemists modify the molecule’s structure to address each issue — adjusting its metabolic stability, membrane permeability, solubility, and pharmacokinetics — while preserving its ability to hit the target.
It determines whether a target is practically druggable
Some targets are biologically validated but chemically intractable — meaning no one has found a way to build a small molecule that can engage them effectively. Whether a target is “druggable” is ultimately a medicinal chemistry question, not a biology question. The decades-long struggle to drug KRAS is one of the defining examples: the biology was clear, but the chemistry was extraordinarily difficult.
The bridge
How medicinal chemistry connects biology to a drug candidate
The work of medicinal chemistry sits between two other kinds of knowledge: structural biology (which reveals the target’s shape) and clinical development (which tests the drug in humans). Medicinal chemistry is the translation layer between understanding a target and having something to put in a pill or an infusion.
Input from structural biology
Structural studies provide a three-dimensional picture of the target protein — its surface contours, binding pockets, and flexible regions. Medicinal chemists use this information to design molecules that fit into specific sites on the protein, much the way a key is shaped to fit a lock. Without structural data, chemistry is largely trial and error. With it, design becomes rational.
The chemistry cycle
Chemists synthesize a candidate molecule, test it for target binding and cellular activity, measure its behavior in biological systems (absorption, metabolism, toxicity), and then redesign based on results. This cycle — make, test, learn, redesign — may repeat hundreds of times before a compound is good enough to advance. Each iteration is informed by structure-activity relationships that reveal which parts of the molecule are critical and which can be changed.
Output to clinical development
The end product of medicinal chemistry is a drug candidate: a single compound with a defined structure, a known mechanism, acceptable safety in preclinical models, and properties that allow it to be manufactured, formulated, and dosed in humans. This compound is what enters phase 1 clinical trials. Everything that happens afterward — dosing, safety, efficacy — depends on the chemical choices made during this stage.
Connection to KRAS and daraxonrasib
Why medicinal chemistry was the bottleneck for KRAS
The target was known for decades before chemistry caught up
KRAS was identified as an oncogene in the early 1980s. Its role in cancer was biologically validated across multiple tumor types. But the protein’s surface was smooth, with no obvious pocket for a small molecule to bind. It held its natural substrate (GTP) with extremely high affinity, making competitive inhibition impractical. For roughly three decades, the central challenge was not biological understanding but chemical tractability — medicinal chemistry was the rate-limiting step.
Covalent chemistry changed the equation
The breakthrough came when medicinal chemists adopted a strategy that had been considered risky: covalent inhibition. Instead of designing a molecule that temporarily occupies a pocket on KRAS, they designed one that forms a permanent chemical bond with a specific amino acid near the switch-II pocket. This approach exploited a structural vulnerability that was only accessible in certain KRAS mutant forms. The chemistry was unconventional, but it worked — and it is the basis for the class of KRAS-directed compounds now in clinical trials, including daraxonrasib.
Daraxonrasib is a direct product of medicinal chemistry. Its structure, binding mode, selectivity profile, and pharmacokinetic properties were shaped through the iterative chemistry process described above. The advances in covalent drug design and structure-guided optimization that emerged over the past decade were preconditions for compounds like it to reach clinical trials in pancreatic cancer.
Branch points in scientific thinking
How medicinal chemistry thinking branched and evolved
Medicinal chemistry is not a single method applied uniformly. The field has branched repeatedly as new tools, strategies, and philosophies of drug design have emerged — and several of these branches directly shaped the path to KRAS-directed drugs.
Reversible vs. covalent inhibition
Should a drug bind temporarily or permanently?
For decades, the dominant philosophy in medicinal chemistry favored reversible inhibitors — molecules that bind a target temporarily and then dissociate. Covalent inhibitors, which form a permanent bond, were considered too risky because of concerns about off-target toxicity. But for targets like KRAS, where reversible binding was insufficient to overcome the protein’s tight grip on GTP, covalent strategies proved essential. The success of covalent KRAS inhibitors has reshaped the field’s attitude toward this approach.
Screening-driven vs. structure-guided design
Start from random libraries or design from the target’s shape?
One branch of medicinal chemistry relies on high-throughput screening — testing thousands or millions of compounds against a target to find initial hits. Another branch starts from the target’s three-dimensional structure and designs molecules rationally. In the KRAS case, early screening efforts largely failed because the protein offered no accessible binding site for conventional libraries. The breakthrough required structure-guided design informed by work from the Shokat lab at UCSF, whose identification of the switch-II pocket opened a binding site that conventional screens had missed entirely.
Mutation-specific vs. pan-RAS approaches
Target one KRAS mutation or all of them?
The first successful covalent KRAS inhibitors were specific to one mutation: G12C. This mutation is common in lung cancer but less so in pancreatic cancer, where G12D and G12V predominate. A major branch in current medicinal chemistry is the effort to develop inhibitors that work against other KRAS mutations or against multiple RAS variants at once. This is one of the active frontiers of the field and is directly relevant to extending KRAS-directed therapy to more pancreatic cancer patients.
Failed and incomplete approaches
Chemistry strategies that did not work — but still advanced the field
The path to a successful KRAS drug was littered with chemical approaches that failed or fell short. Each one taught the field something about what KRAS would and would not allow.
Competitive GTP-binding inhibitors
The most intuitive chemical strategy was to design a molecule that competes with GTP for the active site of KRAS — the way many kinase inhibitors compete with ATP. But KRAS binds GTP with extremely high affinity, and cellular GTP concentrations are high. No competitive inhibitor could achieve the binding strength needed to displace GTP in a living cell. This failure forced the field to look for alternative binding sites entirely.
Protein-protein interaction disruptors
Another approach attempted to block the interaction between KRAS and its downstream effector proteins (such as RAF) by designing molecules that wedge into the protein-protein interface. These interfaces are typically large, flat, and featureless — the opposite of what drug-like molecules engage well. Some compounds showed activity in laboratory settings but could not achieve sufficient potency or selectivity for clinical use. The effort clarified the structural challenges of targeting RAS interactions directly.
Farnesylation-blocking strategies
Farnesyltransferase inhibitors aimed to prevent KRAS from reaching the cell membrane, a step required for its signaling function. The chemistry worked — the inhibitors did block farnesylation — but KRAS could be modified by an alternative enzyme (geranylgeranyltransferase), bypassing the blockade. The lesson was not that the chemistry was wrong, but that the biological redundancy of KRAS membrane attachment defeated the chemical strategy.
Fragment-based approaches with insufficient follow-through
Fragment-based drug discovery — starting with very small, weak- binding molecules and growing them into potent compounds — was applied to KRAS by several groups. Some fragments were found to bind near the switch-II region, providing early validation that the area was chemically accessible. But translating fragment hits into drug-like leads proved difficult without the structural insight and covalent strategies that came later. These early efforts laid groundwork that was built upon by subsequent programs.
What often gets missed
What the public usually does not hear about medicinal chemistry
Medicinal chemistry is one of the most critical steps in drug development, but it is almost invisible in public discussion. When a drug enters clinical trials, the chemistry behind it is rarely explained — and several important aspects of the field remain poorly understood.
A drug is not just a target — it is a specific molecule
Public discussions often say “a drug that targets KRAS” as if targeting were the whole story. In reality, the specific molecular structure of the drug determines everything: how tightly it binds, where in the body it goes, how long it lasts, what side effects it causes, and whether it can be manufactured. Two drugs that target the same protein can behave completely differently because of their chemical structures.
Most drug candidates fail, and that is expected
For every compound that enters clinical trials, hundreds or thousands were made and discarded during lead optimization. Failure in medicinal chemistry is not a sign that the science is broken — it is the mechanism by which the science works. Each failed compound teaches the team something about the target, the chemistry, or the biology that narrows the path toward a better one.
“Drug discovery” is mostly chemistry
The phrase “drug discovery” is often used loosely to describe everything from basic science to clinical trials. In practice, the actual discovery of the drug — the molecule that will be tested in humans — happens in the medicinal chemistry phase. Target identification, signaling research, and structural biology set the stage, but the drug itself is a chemical entity designed and built by chemists.
The chemistry constrains what is clinically possible
Many of the limitations that show up in clinical trials — inadequate duration of response, dose-limiting toxicity, resistance — have their roots in the chemical properties of the drug. A molecule that clears the body too quickly may require doses high enough to cause side effects. A molecule that binds only one mutant form may not help patients with a different mutation. These are not failures of clinical design — they are reflections of what the chemistry could and could not achieve.
Related case
Where this concept appears in TrialLineage
Daraxonrasib in pancreatic cancer
Medicinal chemistry sits near the end of the scientific lineage behind daraxonrasib — the stage where decades of biological understanding, structural insight, and chemical strategy converge into the specific molecule that enters human trials. The case page traces the full discovery chain, from oncogene discovery through signaling biology, pancreatic disease research, structural biology, and clinical translation, showing how a phase 1–3 trial emerges from interrelated research across many fields.
Related concepts
Other scientific fields in the TrialLineage discovery chain.
About this page
This is a TrialLineage concept explainer. Concept pages provide plain-language background on the scientific fields, branch points, and discoveries that underlie specific clinical developments. They are designed to be read independently or as companions to case pages — helping a public audience understand the full discovery process behind a human-disease trial.